Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
HBM Holdings Limited (2142.HK)
Shanghai, CN
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.54% | -2.58% | -10.15% | -3.79% | -13.28% | -3.87% | +30.91% | +579.65% | -0.26% | +6.08% | +6.08% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+315.3% ★ Q4'25: +17.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+2,955.6% ★ Q4'25: -23.7% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%+53.7% ★ Q4'25: +33.5% (vs Q4'23)
-
EBIT margin Biotechnology: +0.0%+51.0% ★ Q4'25: +21.8% (vs Q4'23)
-
ROIC Biotechnology: -16.1%+169.3% ★ Q4'25: +101.3% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+5.0% Q4'25: +26.4% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.98× ★ Q4'25: 1.48× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
14.11M
est: 11.21M (+25.8%)
|
4.31M
est: 9.64M (-55.3%)
|
40.66M
est: 44.76M (-9.2%)
|
89.50M
est: 72.21M (+24.0%)
|
38.10M
est: 35.70M (+6.7%)
|
158.21M
est: 188.12M (-15.9%)
|
231.80M
223.77M – 239.83M
+23.2% YoY
|
232.76M
216.68M – 248.85M
+0.4% YoY
|
260.11M
251.10M – 269.12M
+11.7% YoY
|
201.32M
194.34M – 208.29M
-22.6% YoY
|
239.57M
231.27M – 247.87M
+19.0% YoY
|
| EBITDA |
-290.91M
est: -6.07M (-4,693.3%)
|
-130.84M
est: -5.22M (-2,406.8%)
|
-130.21M
est: -24.22M (-437.5%)
|
31.19M
est: -17.04M (+283.0%)
|
-2.08M
est: -8.42M (+75.3%)
|
83.23M
est: -44.40M (+287.5%)
|
-54.70M
-56.60M – -52.81M
-23.2% YoY
|
-54.93M
-58.73M – -51.14M
-0.4% YoY
|
-61.39M
-63.51M – -59.26M
-11.7% YoY
|
-47.51M
-49.16M – -45.86M
+22.6% YoY
|
-56.54M
-58.50M – -54.58M
-19.0% YoY
|
| EBIT |
-296.54M
est: -6.28M (-4,621.7%)
|
-137.65M
est: -5.40M (-2,448.5%)
|
-135.03M
est: -25.07M (-438.7%)
|
26.55M
est: -18.63M (+242.5%)
|
-3.70M
est: -9.21M (+59.9%)
|
80.70M
est: -48.54M (+266.2%)
|
-59.81M
-61.88M – -57.74M
-23.2% YoY
|
-60.06M
-64.21M – -55.91M
-0.4% YoY
|
-67.12M
-69.44M – -64.79M
-11.7% YoY
|
-51.95M
-53.75M – -50.15M
+22.6% YoY
|
-61.82M
-63.96M – -59.68M
-19.0% YoY
|
| Net Income |
-296.54M
est: -850.61M (+65.1%)
|
-137.88M
est: -124.77M (-10.5%)
|
-137.27M
est: -142.46M (+3.6%)
|
22.80M
|
2.78M
est: -5.69M (+148.8%)
|
91.47M
est: 57.33M (+59.5%)
|
72.21M
68.96M – 75.47M
+26.0% YoY
|
83.58M
54.59M – 94.37M
+15.7% YoY
|
98.57M
94.13M – 103.01M
+17.9% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| SGA |
46.29M
est: 14.25M (+224.9%)
|
10.33M
est: 12.26M (-15.8%)
|
10.08M
est: 56.88M (-82.3%)
|
20.56M
est: 46.95M (-56.2%)
|
7.55M
est: 23.21M (-67.5%)
|
28.30M
est: 122.33M (-76.9%)
|
150.72M
145.50M – 155.95M
+23.2% YoY
|
151.35M
140.89M – 161.81M
+0.4% YoY
|
169.14M
163.28M – 175.00M
+11.7% YoY
|
130.90M
126.37M – 135.44M
-22.6% YoY
|
155.78M
150.38M – 161.17M
+19.0% YoY
|
| EPS |
-1.69
est: -1.10 (-53.5%)
|
-0.19
est: -0.16 (-17.6%)
|
-0.19
est: -0.18 (-3.0%)
|
0.03
|
0.00
est: -0.01 (+151.3%)
|
0.12
est: 0.07 (+69.7%)
|
0.09
0.09 – 0.09
+26.0% YoY
|
0.09
0.07 – 0.12
+3.1% YoY
|
0.12
0.12 – 0.13
+32.3% YoY
|
—
— – —
-100.0% YoY
|
—
— – —
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 2/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 4/5 | 5/5 | 2/5 | 3/5 | 2/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 2/5 |
| 2026-04-17 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
| 2026-04-16 | B | 3/5 | 1/5 | 4/5 | 5/5 | 1/5 | 2/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | WisdomTree China ex-State-Owned Enterprises Fund CXSE | 0.11% | 564.1K | 0.32% |
| 2 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.11% | 1.20M | 0.40% |
| 3 | iShares International Small-Cap Equity Factor ETF ISCF | 0.10% | 646.3K | 0.24% |
| 4 | iShares Ageing Population UCITS ETF AGED.L | 0.08% | 722.0K | 0.40% |
| 5 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.08% | 55.0K | 0.74% |
| 6 | Goldman Sachs Innovate Equity ETF GINN | 0.07% | 157.6K | 0.50% |
| 7 | State Street SPDR S&P Emerging Markets Small Cap ETF EWX | 0.07% | 474.9K | 0.65% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.06% | 67.2K | 0.42% |
| 9 | State Street SPDR S&P China ETF GXC | 0.05% | 207.5K | 0.59% |
| 10 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 2.07M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jingsong Wang | Founder, Chairman & Chief Executive Officer | 9M | — |
| Yiping Rong | Chief Scientific Officer & Executive Director | 3M | — |
| Ian Y. Liu | Senior Vice President & Global Head of Legal and Joint Company Secretary | — | — |
| Michael D. Patten | Chief Strategy Officer & Head of Global Alliance | — | male |
| Peter F. Moesta | Member of Scientific Advisory Board & Chief CMC Advisor | — | — |
| Raymond S. Zheng | Chief Business Officer | — | — |
| Steve Arkinstall DPhil | Chief Scientific Advisor | — | — |
| Xiaolu Tao | Chief Development Officer | — | — |
| Ben Chih | Chief Scientific Officer of Neurosciences - Harbour BioMed US | — | — |
| Youchen Chen | Vice President, Chief Financial Officer & Investor Relations | — | male |
| C. Adam Zong | President | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2142.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
